The 2026 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was held in Jinan, China. At the meeting, Professor Qiang Wei of the Department of Urology at West China Hospital, Sichuan University, presented a poster based on real-world data from the US Veterans Health Administration (VHA), focusing on patients with newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC) who were older, frail, or had a high burden of comorbidities.

Prostate cancer is one of the most common malignancies among men in China, and its development and progression are closely associated with androgens. Consequently, androgen deprivation therapy (ADT) remains an indispensable cornerstone throughout the prostate cancer disease continuum, from localized disease and metastatic hormone-sensitive prostate cancer to castration-resistant prostate cancer.

Pathological diagnosis is the cornerstone of precision breast cancer care. In recent years, rapid advances in digital scanning, artificial intelligence (AI), and multimodal integration have driven a profound transformation in breast pathology, moving it beyond traditional morphological diagnosis toward a digital and intelligent paradigm. These developments offer new tools and evidence to support precise breast cancer classification, treatment response prediction, and individualized therapy. The 17th Yanzhao Breast Cancer Forum was held in Shijiazhuang from August 26 to 30, 2026. During the meeting, Oncology Frontier invited Professor Hong Bu of West China Hospital, Sichuan University, to discuss the development of digital and intelligent breast pathology, drawing on his presentation entitled “The Development of Digital and Intelligent Breast Pathology.” He shared his insights into the key stages of development, the clinical implementation of AI and human–AI collaboration, the digital transformation of pathology, and its clinical value.

The 17th Yanzhao Breast Cancer Forum was held in Shijiazhuang from August 26 to 30, 2026. Jointly organized by the Beijing Breast Disease Prevention and Treatment Society and the Hebei Clinical Oncology Society, and hosted by the Hebei Provincial Breast Disease Diagnosis and Treatment Center and the Breast Center of the Fourth Hospital of Hebei Medical University, the forum adhered to its guiding principles of “pragmatism, standardization, and development.” It brought together leading breast cancer experts from across China for in-depth discussions on key topics, including surgery, systemic therapy, pathological diagnosis, and multidisciplinary collaboration. During the meeting, Oncology Frontier invited Professor Yunjiang Liu of the Fourth Hospital of Hebei Medical University for an exclusive interview. He shared his insights into breast surgery practices in Hebei Province, the design of training programs in oncoplastic and reconstructive techniques, and strategies for extending these techniques to primary-level hospitals.

The 17th Yanzhao Breast Cancer Forum was held in Shijiazhuang from August 26 to 30, 2026. Continuing the forum's longstanding academic tradition, this year's meeting featured a series of lectures by leading experts from across China, who engaged in in-depth discussions on key topics in breast cancer diagnosis and treatment, as well as specialty development. The multidisciplinary team (MDT) case discussion session was another major component of the forum, focusing on the central role of MDT in the comprehensive management of breast cancer and examining the current status and challenges of extending MDT services to primary-level hospitals. During the meeting, Oncology Frontier invited Professor Zhenchuan Song of the Fourth Hospital of Hebei Medical University to share his insights into the academic highlights of the expert lecture series and specialty development, the core value of MDT in comprehensive patient management, and the challenges and strategies involved in promoting MDT at the grassroots level.

The 2026 CSCO Annual Meeting was held in Jinan from September 16 to 19, bringing together scholars from around the world in its international sessions. Prof. Kai-Keen Shiu of the UCL Cancer Institute delivered a special lecture titled “Immuno-resistant CRC treatment” at the conference. Oncology Frontier–UroStream conducted an exclusive interview with him on site, systematically covering the core mechanisms of immunotherapy-resistant colorectal cancer (CRC), breakthrough strategies for microsatellite-stable (MSS) tumors, and practical experience in biomarker testing and patient management. He also shared his assessment of China’s progress in precision therapy and immunotherapy, as well as his expectations for future China–international collaboration, providing valuable reference for CRC treatment in China.